CG Oncology’s (CGON) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of CG Oncology (NASDAQ:CGON) in a research note issued to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $75.00 price objective on the stock.

CGON has been the topic of a number of other research reports. Royal Bank of Canada restated an “outperform” rating and issued a $66.00 price target on shares of CG Oncology in a research note on Friday, December 6th. Morgan Stanley reaffirmed an “overweight” rating and issued a $55.00 target price on shares of CG Oncology in a research report on Friday, March 7th. Finally, TD Cowen assumed coverage on CG Oncology in a report on Tuesday, January 7th. They set a “buy” rating for the company. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $63.88.

CG Oncology Stock Performance

Shares of NASDAQ CGON opened at $26.94 on Tuesday. CG Oncology has a fifty-two week low of $23.91 and a fifty-two week high of $46.99. The business has a 50-day moving average of $27.96 and a 200-day moving average of $31.94.

Insider Activity

In related news, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $29.66, for a total value of $29,660.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Institutional Investors Weigh In On CG Oncology

A number of hedge funds have recently made changes to their positions in the stock. Foresite Capital Management VI LLC acquired a new stake in CG Oncology in the fourth quarter valued at approximately $63,712,000. Marshall Wace LLP boosted its holdings in shares of CG Oncology by 18,836.0% during the 4th quarter. Marshall Wace LLP now owns 1,458,072 shares of the company’s stock valued at $41,818,000 after acquiring an additional 1,450,372 shares in the last quarter. Wellington Management Group LLP grew its position in CG Oncology by 274.4% during the 4th quarter. Wellington Management Group LLP now owns 1,910,470 shares of the company’s stock worth $54,792,000 after acquiring an additional 1,400,251 shares during the last quarter. Acorn Capital Advisors LLC acquired a new position in CG Oncology in the 4th quarter worth about $32,451,000. Finally, Decheng Capital LLC increased its holdings in CG Oncology by 16.3% in the 4th quarter. Decheng Capital LLC now owns 6,371,669 shares of the company’s stock worth $182,739,000 after purchasing an additional 892,859 shares in the last quarter. 26.56% of the stock is currently owned by institutional investors and hedge funds.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.